Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 22, 2011

View Archived Issues

Scientists use Ppp1r15a promoter to develop constructs for tumor-specific imaging

Novo Nordisk reviews highlights fourth quarter 2010

Initial doses of TRC-105 are tolerated in patients with castration-resistant prostate cancer

Promising phase II data on cabozantinib in patients with prostate cancer and soft tissue disease

Quest Diagnostics' proprietary EGF-SERS nanoparticles detect circulating tumor cells in whole blood

Tasquinimod improves PFS in phase II trial in metastatic CRPC

Corticotropin-releasing factor receptor antagonist astressin B activates hair growth in vivo

Prima BioMed receives scientific advice from EMA on CVac trial

EMA committee recommends approval of Sprimeo HCT for hypertension

CHMP recommends change to Humira indication

FDA requires boxed warning for terbutaline for preterm labor

Bayer presents new progesterone receptor antagonists

Novavax reports phase II data on its H1N1 VLP pandemic influenza vaccine

Pharming initiates phase IIIb Rhucin trial in acute hereditary angioedema

Verona Pharma completes trial of RPL-554 in patients with mild asthma

Medivir reports interim data from phase IIb PILLAR trial of TMC-435 in HCV infection

Otuska Pharma's WT1 mRNA assay kit approved for additional use in Japan

Boston Scientific launches Promus and Taxus stent systems in India

MorphoSys receives milestone payment from Novartis in connection with HuCAL technology

Merck Frosst discloses new acyl-CoA desaturase inhibitors

Chelsea Therapeutics prices public offering

Novel histamine receptor modulators presented by Medivation

Eisai reports novel inhibitors of beta-amyloid production

Takeda begins voluntary recall of Dasen in Japan

Merck presents new SCD1 inhibitors for metabolic and other disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...